The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells
- PMID: 31138318
- PMCID: PMC6540516
- DOI: 10.1186/s13046-019-1195-y
The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells
Abstract
Background/aims: A novel paradigm in tumor biology suggests that osteosarcoma (OS) chemo-resistance is driven by osteosarcoma stem cell-like cells (OSCs). As the sensitivity of only a few tumors to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) can be explained by the presence of EGFR tyrosine kinase (TK) domain mutations, there is a need to elucidate mechanisms of resistance to EGFR-targeted therapies in OS that do not harbor TK sensitizing mutations to develop new strategies to circumvent resistance to EGFR inhibitors.
Methods: As a measure of the characters of OSCs, serum-free cultivation, cell viability test with erlotinib, and serial transplantation in vivo was used. Western blot assays were used to detect the association between erlotinib resistance and transforming growth factor beta (TGFβ)-induced epithelial-to-mesenchymal transition (EMT) progression. By using TaqMan qPCR miRNA array, online prediction software, luciferase reporter assays and western blot analysis, we further elucidated the mechanisms.
Results: Here, CD166+ cells are found in 10 out of 10 tumor samples. We characterize that CD166+ cells from primary OS tissues bear hallmarks of OSCs and erlotinib-resistance. TGFβ-induced EMT-associated kinase switch is demonstrated to promote erlotinib-resistance of CD166+ OSCs. Further mechanisms study show that TGFβ-induced EMT decreases miR-499a expression through the direct binding of Snail1/Zeb1 to miR-499a promoter. Overexpression of miR-499a in CD166+ OSCs inhibits TGFβ-induced erlotinib-resistance in vitro and in vivo. SHKBP1, the direct target of miR-499a, regulates EGFR activity reduction occurring concomitantly with a TGFβ-induced EMT-associated kinase switch to an AKT-activated EGFR-independent state. TGFβ-induced activation of AKT co-opts an increased SHKBP1 expression, which further regulates EGFR activity. In clinic, the ratio of the expression levels of SHKBP1 and miR-499a is highly correlated with EMT and resistance to erlotinib.
Conclusion: TGFβ-miR-499a-SHKBP1 network orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors in CD166+ OSCs, implies that inhibition of TGFβ induced EMT-associated kinase switch may reverse the chemo-resistance of OSCs to EGFR inhibitors. We also suggest that an elevated SHKBP1/miR-499a ratio is a molecular signature that characterizes the erlotinib-resistant OS, which may have clinical value as a predictive biomarker.
Keywords: EGFR; Epithelial-to-mesenchymal transition; Osteosarcoma stem cell-like cells; SHKBP1; TGFβ; miR-499a.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6540516/bin/13046_2019_1195_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6540516/bin/13046_2019_1195_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6540516/bin/13046_2019_1195_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6540516/bin/13046_2019_1195_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6540516/bin/13046_2019_1195_Fig5_HTML.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6540516/bin/13046_2019_1195_Fig6_HTML.gif)
![Fig. 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6540516/bin/13046_2019_1195_Fig7_HTML.gif)
![Fig. 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6540516/bin/13046_2019_1195_Fig8_HTML.gif)
Similar articles
-
The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.Cancer Res. 2014 Jul 15;74(14):3995-4005. doi: 10.1158/0008-5472.CAN-14-0110. Epub 2014 May 15. Cancer Res. 2014. PMID: 24830724 Free PMC article.
-
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.J Clin Invest. 2014 Jul;124(7):3003-15. doi: 10.1172/JCI73048. Epub 2014 Jun 9. J Clin Invest. 2014. PMID: 24911146 Free PMC article.
-
LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial-Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway.Int J Mol Sci. 2022 Oct 31;23(21):13237. doi: 10.3390/ijms232113237. Int J Mol Sci. 2022. PMID: 36362025 Free PMC article.
-
EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells.Adv Cancer Res. 2020;147:161-188. doi: 10.1016/bs.acr.2020.04.003. Epub 2020 Jun 15. Adv Cancer Res. 2020. PMID: 32593400 Review.
-
Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.Invest New Drugs. 2019 Feb;37(1):175-183. doi: 10.1007/s10637-018-0684-8. Epub 2018 Oct 24. Invest New Drugs. 2019. PMID: 30353245 Review.
Cited by
-
Nε-(1-Carboxymethyl)-L-lysine/RAGE Signaling Drives Metastasis and Cancer Stemness through ERK/NFκB axis in Osteosarcoma.Int J Biol Sci. 2024 Jan 12;20(3):880-896. doi: 10.7150/ijbs.90817. eCollection 2024. Int J Biol Sci. 2024. PMID: 38250151 Free PMC article.
-
DLX2 promotes osteosarcoma epithelial-mesenchymal transition and doxorubicin resistance by enhancing HOXC8-CDH2 axis.iScience. 2023 Oct 19;26(11):108272. doi: 10.1016/j.isci.2023.108272. eCollection 2023 Nov 17. iScience. 2023. PMID: 38026218 Free PMC article.
-
Regulation of the Epithelial to Mesenchymal Transition in Osteosarcoma.Biomolecules. 2023 Feb 20;13(2):398. doi: 10.3390/biom13020398. Biomolecules. 2023. PMID: 36830767 Free PMC article. Review.
-
The Role of Tumor Microenvironment in Regulating the Plasticity of Osteosarcoma Cells.Int J Mol Sci. 2022 Dec 18;23(24):16155. doi: 10.3390/ijms232416155. Int J Mol Sci. 2022. PMID: 36555795 Free PMC article. Review.
-
TGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer.Pharm Res. 2023 Mar;40(3):689-699. doi: 10.1007/s11095-022-03461-1. Epub 2022 Dec 20. Pharm Res. 2023. PMID: 36539669
References
-
- Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J, Bielack S, et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013;31(18):2303–2312. doi: 10.1200/JCO.2012.43.8598. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous